Navigation Links
MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
Date:2/1/2011

MARIETTA, Ga., Feb. 1, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that they will be attending the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, February 15 – 19, 2011.  The meeting will be held at the San Diego Convention Center in San Diego, California.  

MiMedx reported that it will have a sizable presence at AAOS this year to present the potential  numerous trauma, sports medicine, spine and wound care applications that are being developed with the Company's three technologies, CollaFix™, HydroFix™ and its newest technology, AmnioFix™.   During the week of the conference, MiMedx plans to hold various meetings with physicians and scientists to demonstrate the benefits of its current and potential products and implants and share the progress being made in its CollaFix™ technology.

MiMedx recently acquired its AmnioFix™ technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion® process.

MiMedx Group will be located in Booth 5915 at the San Diego Conference Center.  

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. Stunning Attendance for ChemOutsourcing Show on September 8-9 in Long Branch, NJ
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
8. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
9. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
10. Early-Bird Pricing Ends Soon for MichBio Expo Attendees and Exhibitors; Award Nominations Due Nov. 1
11. National Ergonomics Expo Sees 86% On-Site Exhibitor Renewal Rate for 2009; New Products from Contour Design, Equipois, Goldtouch and Herman Miller Win 2008 NECE Attendees Choice New Product Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
Breaking Biology News(10 mins):